Information Provided By: 
Fly News Breaks for February 18, 2020
EIDX
Feb 18, 2020 | 07:32 EDT
Barclays analyst Gena Wang downgraded Eidos Therapeutics (EIDX) to Underweight from Equal Weight with an unchanged price target of $45. While the analyst believes AG-10 could be as good as Pfizer's (PFE) tafamidis and that the ATTRibute-CM Phase 3 study in ATTR-CM will likely be positive, she believes tafamidis launch trajectory has so far been largely in line with expectation and Eidos shares fully reflect the market opportunity. As such, and given a lack of other major catalysts, Wang believes other companies could provide more upside potential.
News For EIDX From the Last 2 Days
There are no results for your query EIDX
